UNSPSC 51172434: Belladonna/kaolin/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.

UNSPSC 51172434 Belladonna/kaolin/phenobarbital is a Commodity code that nominally designates a specific pharmaceutical formulation, but state and local procurement activity under this code encompasses a broader pharmaceutical and laboratory testing services market. Recent state and local solicitations show activity in drug testing services, generic pharmaceutical supply, and pharmacy benefit program development rather than procurement of the specific belladonna compound. Issuing bodies include county departments of corrections and supervision, state health and human services agencies, and cooperative purchasing alliances serving multiple states and localities. The scope of work being solicited ranges from specimen collection and drug testing operations (including immunoassay screening, LC/MS/MS confirmation, and alternative testing methodologies) to generic multi-source pharmaceutical supply agreements and exploratory procurement for direct-to-manufacturer prescription programs.

Geographic activity centers on Texas and Minnesota, with recent opportunities posted by Collin County Community Supervision and Corrections Department (RFP 2026-327, due July 23, 2026, for offender specimen collection and drug testing services estimated at $600,000 over two years with optional renewal; annual testing demand is approximately 25,031 tests), the Texas Health and Human Services Commission (RFI HHS0017013, posted April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program), and the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with contract effectiveness July 1, 2026). The mismatch between the code's nominal pharmaceutical designation and the actual procurement scope suggests that this Commodity code shows limited direct activity for the specific formulation named; opportunities tagged to this code reflect broader pharmaceutical and laboratory procurement rather than targeted demand for belladonna/kaolin/phenobarbital products.